Top

Published in:

01-06-2017 | Original Article

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients

Authors: Arezou Sayad, Soudeh Ghafouri-Fard, Mir Davood Omrani, Rezvan Noroozi, Mohammad Taheri

Published in: Neurological Sciences | Issue 6/2017

Abstract

Multiple sclerosis (MS) is a heterogeneous immune-related demyelinating disorder of central nervous system with several genetic and environmental factors contributing in its pathogenesis or patients’ response to therapies. Myxovirus resistance protein A (MxA) is among the genes which are induced by IFNβ and are involved in the MS pathogenesis and/or response to IFNβ. In the present case-control study, we evaluated the association between three SNPs at nt −123 (A or C, rs17000900), nt −88 (G or T, rs2071430), and nt +20 (A or C, rs464138) and MS risk as well as treatment response in a population of Iranian MS patients including 146 IFNβ responders and 85 non-responders as well as 180 healthy controls. The AGA (−123, −88, +20) haplotype was more frequent in controls compared with MS cases (P = 0.038, OR (95% CI) = 1.77 (1.03–3.02)). Of particular note, the frequency of rs464138 AA genotype was significantly higher in responders compared with non-responders. However, the allele and genotype frequencies of other SNPs were not significantly different among patient subtypes or between patients and controls. Besides, we have demonstrated that CGC, ATA, and AGA (−123, −88, +20) haplotypes were significantly associated with IFNβ response in MS patients. As SNPs on MxA promoter region might participate in MS patients’ response to IFNβ, prior patients genotyping may increase the rate of responsiveness and help in individualized selection of treatment options.

Hamedani SY, Taheri M, Omrani MD, Sajjadi E, Mazdeh M, Panah AST, Sayad A (2016) Up regulation of MMP9 gene expression in female patients with multiple sclerosis. Hum Antibodies (Preprint):1–6

Etemadifar M, Nourian SM, Akbari M, Abtahi SH, Nasri P, Fereidan-Esfahani M (2015) The distinctive contrast of multiple sclerosis epidemiology between Persians and Armenian minority community of Isfahan city, Iran. Neurol Sci 36(4):657–658. doi:10.1007/s10072-014-2013-0 CrossRefPubMed

Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl. 1):1–5CrossRefPubMed

Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S (2014) Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian multiple sclerosis study group (vol 35, pg 307, 2014). Neurol Sci 35(10):1645–1646. doi:10.1007/s10072-014-1649-0 CrossRef

Esposti LD, Piccinni C, Sangiorgi D, Perrone V, Aledda L, Marrosu MG, Lombardo F (2017) Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurol Sci. doi:10.1007/s10072-016-2806-4 PubMed

Bertolotto A, Granieri L, Marnetto F, Valentino P, Sala A, Capobianco M, Malucchi S, Di Sapio A, Malentacchi M, Matta M, Caldano M (2015) Biological monitoring of IFN-beta therapy in multiple sclerosis. Cytokine Growth F R 26(2):241–248. doi:10.1016/j.cytogfr.2014.12.002 CrossRef

Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, Inoko H, Akbari MT, Noroozi R, Hajilooi M (2016) HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis. Pharmacogenomics 17(5):489–498CrossRefPubMed

Bertolotto A (2015) Evaluation of the impact of neutralizing antibodies on IFNβ response. Clin Chim Acta 449:31–36CrossRefPubMed

Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT (2001) Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256(1):141–152CrossRefPubMed

10.

Furuyama H, Chiba S, Okabayashi T, Yokota S, Nonaka M, Imai T, Fujii N, Matsumoto H (2006) Single nucleotide polymorphisms and functional analysis of MxA promoter region in multiple sclerosis. J Neurol Sci 249(2):153–157. doi:10.1016/j.jns.2006.06.012 CrossRefPubMed

11.

Bertolotto A, Granieri L, Marnetto F, Valentino P, Sala A, Capobianco M, Malucchi S, Di Sapio A, Malentacchi M, Matta M (2015) Biological monitoring of IFN-β therapy in multiple sclerosis. Cytokine Growth F R 26(2):241–248CrossRef

12.

Al-Masri A, Heidenreich F, Walter G (2009) Interferon-induced mx proteins in brain tissue of multiple sclerosis patients. Eur J Neurol 16(6):721–726CrossRefPubMed

13.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366 CrossRefPubMedPubMedCentral

14.

Cunningham S, Graham C, Hutchinson M, Droogan A, O’Rourke K, Patterson C, McDonnell G, Hawkins S, Vandenbroeck K (2005) Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 78(6):635–646. doi:10.1016/j.clpt.2005.08.018 CrossRefPubMed

15.

Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H (2004) Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 11(3):271–276. doi:10.1111/j.1365-2893.2004.00509.x CrossRefPubMed

16.

Noguchi S, Hijikata M, Hamano E, Matsushita I, Ito H, Ohashi J, Nagase T, Keicho N (2013) MxA transcripts with distinct first exons and modulation of gene expression levels by single-nucleotide polymorphisms in human bronchial epithelial cells. Immunogenetics 65(2):107–114. doi:10.1007/s00251-012-0663-8 CrossRefPubMed

17.

Duc TTT, Desmecht D, Cornet A (2013) Functional characterization of new allelic polymorphisms identified in the promoter region of the human MxA gene. Int J Immunogenet 40(4):316–319. doi:10.1111/j.1744-313X.2012.01153.x CrossRef

18.

Weinstock-Guttman B, Tamano-Blanco M, Bhasi K, Zivadinov R, Ramanathan M (2007) Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. J Neuroimmunol 182(1–2):236–239. doi:10.1016/j.jneuroim.2006.10.011 CrossRefPubMed

19.

Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y (2001) Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and -88) in vivo and in vitro. Intervirology 44(6):379–382. doi:10.1159/000050075 CrossRefPubMed

20.

Gniadek P, Aktas O, Wandinger KP, Bellmann-Strobl J, Wengert O, Weber A, von Wussow P, Obert HJ, Zipp F (2003) Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J Neuroimmunol 137(1–2):187–196. doi:10.1016/S0165-5728(03)00074-2 CrossRefPubMed

21.

Ward LD, Kellis M (2016) HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res 44(D1):D877–D881. doi:10.1093/nar/gkv1340 CrossRefPubMed

22.

Abrajano JJ, Qureshi IA, Gokhan S, Zheng DY, Bergman A, Mehler MF (2009) REST and CoREST modulate neuronal subtype specification, maturation and maintenance. PLoS One 4(12):e7936. doi:10.1371/journal.pone.0007936 CrossRefPubMedPubMedCentral

23.

Liggett T, Melnikov A, Tilwalli S, Yi QL, Chen HY, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V (2010) Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci 290(1–2):16–21. doi:10.1016/j.jns.2009.12.018 CrossRefPubMedPubMedCentral

24.

Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13(4):554–573CrossRefPubMed

25.

Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, Wei J, Varga J (2013) p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis. J Investig Dermatol 133(5):1302–1310CrossRefPubMedPubMedCentral

26.

Rahmani Z, Blouin JL, Creaugoldberg N, Watkins PC, Mattei JF, Poissonnier M, Prieur M, Chettouh Z, Nicole A, Aurias A, Sinet PM, Delabar JM (1989) Critical role of the D21s55 region on chromosome-21 in the pathogenesis of down syndrome. Proc Natl Acad Sci USA 86(15):5958–5962. doi:10.1073/pnas.86.15.5958 CrossRefPubMedPubMedCentral

27.

Horisberger MA (1995) Interferons, mx-genes, and resistance to influenza-virus. Am J Resp Crit Care 152(4):S67–S71CrossRef

28.

Weilbach FX, Toyka KV (2002) Does Down’s syndrome protect against multiple sclerosis? Eur Neurol 47(1):52–55CrossRefPubMed

Title: Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients
Authors: Arezou Sayad
Soudeh Ghafouri-Fard
Mir Davood Omrani
Rezvan Noroozi
Mohammad Taheri
Publication date: 01-06-2017
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 6/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-017-2935-4

2024 ASCO Annual Meeting

Springer Medicine

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

Highlights of issue 6, 2017

Serum uric acid levels and freezing of gait in Parkinson’s disease

Edinburgh Cognitive and Behavioural ALS Screen (ECAS)-Italian version: regression based norms and equivalent scores

Blink reflex habituation in migraine and chronic tension-type headache

The mystery of unexplained traumatic sudden falls. A clinical case that adds a new feasible cause

Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS)